Evidence map›Paper›PMID 37575756›Full record

ReviewCureus2023

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus.

Fnu Jyotsna, Kamran Mahfooz, Tirath Patel, Fnu Parshant, Fnu Simran, Fnu Harsha, Fnu Neha, Dev Jyotishna, Dipesh Mishra, Sirjana Subedi and 3 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 8 countries.

Fnu JyotsnaMedicine, DR. B.R. (Bharatha Rathna) Ambedkar Medical College & Hospital, Bengaluru, IND.
Kamran MahfoozInternal Medicine, Lincoln Medical Center, New York, USA.
Tirath PatelMedical Student, American University of Antigua, St. John's, ATG.
Fnu ParshantMedicine, Jinnah Sindh Medical University, Karachi, PAK.
Fnu SimranMedicine, Jinnah Sindh Medical University, Karachi, PAK.
Fnu HarshaMedicine, Jinnah Sindh Medical University, Karachi, PAK.
Fnu NehaMedicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Dev JyotishnaCardiology, TU (Tribhuvan University) Teaching Hospital, International Organization for Migration, Mohali, NPL.
Dipesh MishraMedicine, Chirayu National Hospital and Medical Institute, Kathmandu, NPL.
Sirjana SubediMedicine, University of Medicine and Health Sciences, Basseterre, NPL.
Mahima KhatriMedicine and Surgery, Dow University of Health Sciences, Karachi, PAK.
Satesh KumarMedicine and Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, PAK.
Giustino VarrassiPain Medicine, Paolo Procacci Foundation, Rome, ITA.
Jinnah Sindh Medical University · PKAmbedkar University Delhi · INAmerican University of Antigua · AGDow University of Health Sciences · PKFondazione Roma · ITInternational Organization for Migration · CHKathmandu Medical College Teaching Hospital · NPLincoln Medical Center · USShaheed Mohtarma Benazir Bhutto Medical University · PKSree Gokulam Medical College and Research Foundation · INUniversity of Medicine and Health Sciences · KN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study is to assess the safety and efficacy of finerenone therapy in type 2 diabetes mellitus (T2DM) patients with cardiovascular and chronic renal diseases. This meta-analysis assesses the efficacy and safety of finerenone in the treatment of diabetic kidney disease (DKD). A comprehensive search of PubMed, Embase, and Google Scholar databases was performed to identify relevant randomized controlled trials (RCTs). To quantify the effects of finerenone, the analysis included the estimation of aggregated mean differences (MDs) and relative risks (RRs), as well as 95% confidence intervals (CIs). This meta-analysis included seven double-blind trials with patients suffering from chronic kidney disease (CKD) and T2D. Participants received finerenone or a placebo was assigned at random. The primary efficacy outcomes were cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, kidney failure, a sustained 57% decrease in the estimated glomerular filtration rate from baseline over four weeks, or renal death. Among the 39,995 patients included in the analysis, finerenone treatment was associated with a lower risk of cardiovascular and renal-related mortality compared to placebo (RR = 0.86 (0.80, 0.93), p = 0.0002; I-squared statistic (I

Indexed as

cardiovascular diseasechronic kidney diseaseckddiabetesfinerenonemeta-analysisnon-steroidal mineralocorticoid receptor antagonist

Identifiers

PMID37575756
PMCPMC10421409
OpenAlexW4384067472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.